Moderna price target raised to $151 from $143 at UBS

UBS analyst Eliana Merle raised the firm’s price target on Moderna to $151 from $143 and keeps a Buy rating on the shares. UBS see continued upside for shares, and a potential inflection on the horizon with cytomegalovirus Phase 3 data potentially later this year and individualized neoantigen therapy Phase 3 trials under way, the analyst tells investors in a research note.